

---

# 5.90.030

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupilumab	<b>Page:</b>	1 of 19

---

**Last Review Date:** March 7, 2025

---

## Dupilumab

### Description

#### Dupilumab (dupilumab)

---

#### Background

Dupilumab (dupilumab) is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the interleukin-4 receptor alpha (IL-4R $\alpha$ ) subunit shared by the IL-4 and IL-13 receptor complexes. This blocks the IL-4 and IL-13 cytokine-induced inflammatory responses, including the release of proinflammatory cytokines, chemokines, nitric oxide, and IgE; however, the mechanism of action for Dupilumab has not been definitively established (1).

#### Regulatory Status

FDA-approved indications: Dupilumab is an interleukin-4 receptor alpha antagonist indicated: (1)

1. Atopic Dermatitis
  - a. For the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupilumab can be used with or without topical corticosteroids.
2. Asthma
  - a. As an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
    - i. Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus.
3. Chronic Rhinosinusitis with Nasal Polyps

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupixent	<b>Page:</b>	2 of 19

---

- a. As an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
4. Eosinophilic Esophagitis
  - a. For the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).
5. Prurigo Nodularis
  - a. For the treatment of adult patients with prurigo nodularis (PN).
6. Chronic Obstructive Pulmonary Disease (COPD)
  - a. As an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
    - i. Limitations of Use: Not for the relief of acute bronchospasm.

Dupixent has warnings for hypersensitivity reactions, conjunctivitis and keratitis, and parasitic infections. Patients should be monitored and Dupixent treatment should be discontinued if appropriate (1).

Patients should not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of Dupixent therapy. Steroids should be reduced gradually, if appropriate (1).

FEP adherence is defined as  $\geq 50\%$  utilization within the last 180 days.

Dupixent is approved to treat both asthma and COPD. Patients with features of both these conditions should follow treatment for asthma, per the Global Initiative for Asthma (GINA) report (2).

The safety and effectiveness of Dupixent in pediatric patients less than 6 months of age with atopic dermatitis have not been established. The safety and effectiveness of Dupixent in pediatric patients less than 6 years of age with asthma have not been established. The safety and effectiveness of Dupixent in pediatric patients less than 1 year of age with eosinophilic esophagitis have not been established. The safety and effectiveness of Dupixent in pediatric patients less than 12 years of age with CRSwNP have not been established. The safety and effectiveness of Dupixent in pediatric patients less than 18 years of age with PN and COPD have not been established (1).

---

### **Related policies**

Adbry, Cibinqo, Cinqair, Doxepin cream 5%, Eohilia, Eucrisa, IL-5 Antagonists, Nemluvio, Rinvoq, Tezspire, Xolair

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupixent	<b>Page:</b>	3 of 19

---

## Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Dupixent may be considered **medically necessary** if the conditions indicated below are met.

Dupixent may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 6 months of age or older

### Diagnosis

Patient must have the following:

Moderate-to-severe atopic dermatitis (AD) (eczema)

**AND** submission of medical records (e.g., chart notes, laboratory values) documenting the following:

1. Inadequate treatment response, intolerance, or contraindication to **ONE** medication in **EACH** of the following categories:
  - a. 18 years of age or older:
    - a. Topical calcineurin inhibitor (see Appendix 1)
    - b. **High** potency topical corticosteroid (see Appendix 2)
  - b. 2 to 17 years of age:
    - a. Topical calcineurin inhibitor (see Appendix 1)
    - b. Topical corticosteroid (see Appendix 2)
  - c. 6 months to less than 2 years of age:
    - a. Topical corticosteroid (see Appendix 2)
2. Baseline evaluation of the condition using **ONE** of the following scoring tools:
  - a. Investigator's Static Global Assessment (ISGA) with a score  $\geq 3$  (e.g., [https://www.eczemaouncil.org/assets/docs/Validated-Investigator-Global-Assessment-Scale\\_vIGA-AD\\_2017.pdf](https://www.eczemaouncil.org/assets/docs/Validated-Investigator-Global-Assessment-Scale_vIGA-AD_2017.pdf))
  - b. Eczema Area and Severity Index (EASI) with a score  $\geq 16$  (e.g., <https://dermnetnz.org/topics/easi-score/>)

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupixent	<b>Page:</b>	4 of 19

---

- c. Patient-Oriented Eczema Measure (POEM) with a score  $\geq 8$   
(e.g., <https://jamanetwork.com/data/Journals/DERM/11776/dea40003f1.png>)
- d. Scoring Atopic Dermatitis (SCORAD) index with a score  $\geq 15$   
(e.g., <https://dermnetnz.org/topics/scorad/>)
3. **NOT** used in combination with another non-topical Prior Authorization (PA) medication for atopic dermatitis (see Appendix 3)
4. **NOT** given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

---

**Age** 6 years of age or older

## Diagnosis

Patient must have the following:

Moderate-to-severe asthma

**AND** submission of medical records (e.g., chart notes, laboratory values) and use of claims history documenting the following:

1. Patient has **ONE** of the following:
  - a. Asthma with eosinophilic phenotype with eosinophil count greater than or equal to 150 cells/mcL in the past 90 days **OR** 300 cells/mcL in the past 12 months
  - b. Oral corticosteroid dependent asthma with **ONE** of the following:
    - i. 1 month of daily oral corticosteroid use within the last 3 months
    - ii. Patient currently requires oral corticosteroids
2. Exacerbation history in the past year of **ONE** of the following:
  - a.  $\geq 2$  moderate asthma exacerbations
  - b.  $\geq 1$  severe asthma exacerbation leading to hospitalization
3. Inadequate control of asthma symptoms after a minimum of 3 months of compliant use with greater than or equal to 50% adherence with **ONE** of the following within the past 6 months:
  - a. Inhaled corticosteroids & long acting beta<sub>2</sub> agonist
  - b. Inhaled corticosteroids & long acting muscarinic antagonist

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupixent	<b>Page:</b>	5 of 19

---

4. **NOT** used for the emergency relief of acute bronchospasm or status asthmaticus
5. **NO** dual therapy with another monoclonal antibody for the treatment of asthma or COPD (see Appendix 4)
6. **NOT** given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

---

**Age** 1 year of age or older

### Diagnosis

Patient must have the following:

Eosinophilic esophagitis (EoE)

**AND** submission of medical records (e.g., chart notes, laboratory values) documenting the following:

1. Patient has  $\geq 15$  intraepithelial eosinophils per high-power field (eos/hpf)
2. Symptoms of dysphagia (e.g., pain while swallowing, drooling, sensation of food getting stuck in the throat or chest)
3. Inadequate treatment response, intolerance, or contraindication to a proton pump inhibitor (PPI)
4. Patient weight  $\geq 15$  kg
5. **NOT** given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

---

**Age** 12 years of age or older

### Diagnosis

Patient must have the following:

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupixent	<b>Page:</b>	6 of 19

---

Chronic rhinosinusitis with nasal polyps (CRSwNP)

**AND** submission of medical records (e.g., chart notes, laboratory values) documenting the following:

1. Inadequate treatment response, intolerance, or contraindication to a 3-month trial of **EACH** of the following:
  - a. **TWO** nasal corticosteroid sprays
  - b. **ONE** oral corticosteroid
2. Prescribed by or recommended by an otolaryngologist (ENT)
3. **NO** dual therapy with another monoclonal antibody for the treatment of CRSwNP (see Appendix 5)
4. **NOT** given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

---

**Age** 18 years of age or older

## Diagnosis

Patient must have the following:

Prurigo nodularis (PN)

**AND** submission of medical records (e.g., chart notes, laboratory values) documenting the following:

1. Inadequate treatment response, intolerance, or contraindication to a **high** potency topical steroid (see Appendix 2)
2. Inadequate treatment response, intolerance, or contraindication to either conventional systemic therapy (i.e., cyclosporine, methotrexate) or phototherapy
  - i. If the patient is intolerant or contraindicated to one therapy then the patient must have an inadequate treatment response, intolerance, or contraindication to the other treatment option

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupixent	<b>Page:</b>	7 of 19

---

3. Baseline evaluation of the condition using the Investigator's Global Assessment (IGA) for prurigo nodularis with a score  $\geq 3$  (e.g., [https://www.medicaljournals.se/acta/html-editor/table-pdf/big/5947/5947\\_30402.png](https://www.medicaljournals.se/acta/html-editor/table-pdf/big/5947/5947_30402.png))
3. **NOT** given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

---

**Age** 18 years of age or older

## Diagnosis

Patient must have the following:

Chronic obstructive pulmonary disease (COPD)

**AND** submission of medical records (e.g., chart notes, laboratory values) documenting the following:

1. Patient has **ONE** of the following
  - a. Eosinophil count greater than or equal to 150 cells/mcL in the past 90 days **OR** 300 cells/mcL in the past 12 months
  - b. Oral corticosteroid dependent COPD with **ONE** of the following:
    - i. 1 month of daily oral corticosteroid use within the last 3 months
    - ii. Patient currently requires oral corticosteroids
2. Exacerbation history in the past year of **ONE** of the following:
  - a.  $\geq 2$  moderate COPD exacerbations
  - b.  $\geq 1$  severe COPD exacerbation leading to hospitalization
3. Inadequate control of COPD symptoms after a minimum of 3 months of compliant use with greater than or equal to 50% adherence with **ONE** of the following within the past 6 months:
  - a. Long acting beta<sub>2</sub> agonist & long acting muscarinic antagonist & inhaled corticosteroid
  - b. Long acting beta<sub>2</sub> agonist & long acting muscarinic antagonist if inhaled corticosteroids are contraindicated
4. **NOT** used for the emergency relief of acute bronchospasm

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupixent	<b>Page:</b>	8 of 19

---

5. **NO** dual therapy with another monoclonal antibody for the treatment of asthma or COPD (see Appendix 4)
6. **NOT** given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

---

## Prior – Approval *Renewal* Requirements

**Age** 6 months of age or older

### Diagnosis

Patient must have the following:

Atopic dermatitis (AD) (eczema)

**AND** submission of medical records (e.g., chart notes, laboratory values) documenting the following:

1. Documented improvement of the condition using **ONE** of the following scoring tools:
  - a. ISGA – decrease from baseline by at least 2 points  
(e.g., [https://www.eczemacouncil.org/assets/docs/Validated-Investigator-Global-Assessment-Scale\\_vIGA-AD\\_2017.pdf](https://www.eczemacouncil.org/assets/docs/Validated-Investigator-Global-Assessment-Scale_vIGA-AD_2017.pdf))
  - b. EASI – decrease from baseline by at least 75%  
(e.g., <https://dermnetnz.org/topics/easi-score/>)
  - c. POEM – decrease from baseline by at least 3 points  
(e.g., <https://jamanetwork.com/data/Journals/DERM/11776/dea40003f1.png>)
  - d. SCORAD – decrease from baseline by at least 50%  
(e.g., <https://dermnetnz.org/topics/scorad/>)
2. Patient has been adherent to Dupixent therapy
3. **NOT** used in combination with another non-topical Prior Authorization (PA) medication for atopic dermatitis (see Appendix 3)
4. **NOT** given concurrently with live vaccines

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupixent	<b>Page:</b>	9 of 19

---

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

---

**Age** 6 years of age or older

### Diagnosis

Patient must have the following:

Asthma

**AND** submission of medical records (e.g., chart notes, laboratory values) and use of claims history documenting the following:

1. Decreased exacerbations **OR** improvement in symptoms
2. Patient has been adherent to Dupixent therapy
3. **NOT** used for the emergency relief of acute bronchospasm or status asthmaticus
4. **NO** dual therapy with another monoclonal antibody for the treatment of asthma or COPD (see Appendix 4)
5. **NOT** given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

---

**Age** 1 year of age or older

### Diagnosis

Patient must have the following:

Eosinophilic esophagitis (EoE)

**AND** submission of medical records (e.g., chart notes, laboratory values) and use of claims history documenting the following:

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupixent	<b>Page:</b>	10 of 19

---

1. Decrease in intraepithelial eosinophils per high-power field (eos/hpf) from baseline
2. Improvement in symptoms of dysphagia
3. Patient weight  $\geq$  15 kg
4. Patient has been adherent to Dupixent therapy
5. **NOT** given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

---

**Age** 12 years of age or older

### Diagnosis

Patient must have the following:

Chronic rhinosinusitis with nasal polyps (CRSwNP)

**AND** submission of medical records (e.g., chart notes, laboratory values) and use of claims history documenting the following:

1. Improvement in sino-nasal symptoms
2. Decreased utilization of oral corticosteroids
3. Patient has been adherent to Dupixent therapy
4. **NO** dual therapy with another monoclonal antibody for the treatment of CRSwNP (see Appendix 5)
5. **NOT** given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

---

**Age** 18 years of age or older

### Diagnosis

Patient must have the following:

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupixent	<b>Page:</b>	11 of 19

---

## Prurigo nodularis (PN)

**AND** submission of medical records (e.g., chart notes, laboratory values) and use of claims history documenting the following:

1. Documented improvement of the condition using IGA for prurigo nodularis with a decrease from baseline by at least 2 points  
(e.g., [https://www.medicaljournals.se/acta/html-editor/table-pdf/big/5947/5947\\_30402.png](https://www.medicaljournals.se/acta/html-editor/table-pdf/big/5947/5947_30402.png))
2. Patient has been adherent to Dupixent therapy
3. **NOT** given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

---

**Age** 18 years of age or older

## Diagnosis

Patient must have the following:

Chronic obstructive pulmonary disease (COPD)

**AND** submission of medical records (e.g., chart notes, laboratory values) and use of claims history documenting the following:

1. Decreased exacerbations **OR** improvement in symptoms
2. Patient has been adherent to Dupixent therapy
3. **NOT** used for the emergency relief of acute bronchospasm
4. **NO** dual therapy with another monoclonal antibody for the treatment of asthma or COPD (see Appendix 4)
5. **NOT** given concurrently with live vaccines

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

**Section:** Prescription Drugs**Effective Date:** April 1, 2025**Subsection:** Topical Products**Original Policy Date:** April 7, 2017**Subject:** Dupixent**Page:** 12 of 19**Policy Guidelines****Pre - PA Allowance**

None

**Prior - Approval Limits****Quantity**

<b>Strength</b>	<b>Diagnosis</b>	<b>Quantity</b>
100 mg	Asthma	8 injections per 112 days <b>OR</b>
	Atopic dermatitis	N/A
	Chronic rhinosinusitis with nasal polyps	N/A
	Eosinophilic esophagitis	N/A
	Prurigo nodularis	N/A
	Chronic obstructive pulmonary disease	N/A
200 mg	Asthma	10 injections per 112 days <b>OR</b>
	Atopic dermatitis	
	Chronic rhinosinusitis with nasal polyps	N/A
	Eosinophilic esophagitis	8 injections per 112 days <b>OR</b>
	Prurigo nodularis	N/A
	Chronic obstructive pulmonary disease	N/A
300 mg	Asthma	10 injections per 112 days <b>OR</b>
	Atopic dermatitis	
	Chronic rhinosinusitis with nasal polyps	8 injections per 112 days <b>OR</b>
	Eosinophilic esophagitis	16 injections per 112 days <b>OR</b>
	Prurigo nodularis	10 injections per 112 days <b>OR</b>
	Chronic obstructive pulmonary disease	8 injections per 112 days

**Duration** 16 weeks**Prior – Approval *Renewal* Limits**

**Section:** Prescription Drugs**Effective Date:** April 1, 2025**Subsection:** Topical Products**Original Policy Date:** April 7, 2017**Subject:** Dupixent**Page:** 13 of 19**Quantity**

<b>Strength</b>	<b>Diagnosis</b>	<b>Quantity</b>
100 mg	Asthma	6 injections per 84 days <b>OR</b>
	Atopic dermatitis	N/A
	Chronic rhinosinusitis with nasal polyps	N/A
	Eosinophilic esophagitis	N/A
	Prurigo nodularis	N/A
	Chronic obstructive pulmonary disease	N/A
200 mg	Asthma	6 injections per 84 days <b>OR</b>
	Atopic dermatitis	
	Chronic rhinosinusitis with nasal polyps	N/A
	Eosinophilic esophagitis	6 injections per 84 days <b>OR</b>
	Prurigo nodularis	N/A
	Chronic obstructive pulmonary disease	N/A
300 mg	Asthma	6 injections per 84 days <b>OR</b>
	Atopic dermatitis	
	Chronic rhinosinusitis with nasal polyps	6 injections per 84 days <b>OR</b>
	Eosinophilic esophagitis	12 injections per 84 days <b>OR</b>
	Prurigo nodularis	6 injections per 84 days <b>OR</b>
	Chronic obstructive pulmonary disease	6 injections per 84 days

**Duration** 12 months**Rationale****Summary**

Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist indicated for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps (CRSwNP), prurigo nodularis (PN), and chronic obstructive pulmonary disease (COPD). Dupixent has warnings for hypersensitivity reactions, conjunctivitis and keratitis, and parasitic

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupixent	<b>Page:</b>	14 of 19

infections. Patients should be monitored and Dupixent treatment should be discontinued if appropriate. The safety and effectiveness of Dupixent in pediatric patients less than 6 months of age with atopic dermatitis have not been established. The safety and effectiveness of Dupixent in pediatric patients less than 6 years of age with asthma have not been established. The safety and effectiveness of Dupixent in pediatric patients less than 1 year of age with eosinophilic esophagitis have not been established. The safety and effectiveness of Dupixent in pediatric patients less than 12 years of age with CRSwNP have not been established. The safety and effectiveness of Dupixent in pediatric patients less than 18 years of age with PN and COPD have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Dupixent while maintaining optimal therapeutic outcomes.

### References

1. Dupixent [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals Inc.; September 2024.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Available from [www.ginasthma.org](http://www.ginasthma.org).

### Policy History

Date	Action
April 2017	Addition to PA Addition of EASI, POEM and SCORAD scoring tools to criteria for evaluation
June 2017	Annual review Addition of Dupixent into the Managed PA program Adjustment of the Baseline POEM and SCORAD values
May 2018	Addition of url links for scoring tools
June 2018	Annual editorial review
November 2018	Annual editorial review and reference update. Addition of asthma indication
March 2019	Decreased age requirement for atopic dermatitis from 18 and older to 12 and older and added 200 mg syringes for atopic dermatitis. Added no live vaccines requirement to asthma indication
June 2019	Annual review. Addition of the 50% adherence requirement to the asthma diagnosis
July 2019	Addition of indication: chronic rhinosinusitis with nasal polyposis (CRSwNP)
September 2019	Annual review
June 2020	Decreased age requirement for atopic dermatitis from 12 and older to 6 and older. Revised t/f steroid requirement for pediatric patients. Scoring tool links updated

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupixent	<b>Page:</b>	15 of 19

---

September 2020	Annual review and reference update
March 2021	Annual editorial review. Investigator's Static Global Assessment link updated
May 2021	Revised the asthma eosinophil count to include $\geq 150$ cells/mcL in the past 90 days. Updated Appendix 1 and 2
June 2021	Annual review
November 2021	Changed age requirement for asthma to 6 years and older per newest package insert. Added Dupixent 100mg to dosing chart. Revised initiation days supply and duration to accommodate new strength
December 2021	Annual review
January 2022	Changed requirement to t/f of TWO nasal corticosteroids sprays and ONE oral corticosteroid per FEP
March 2022	Annual review and reference update. Per SME: Changed asthma renewal requirement to "decreased exacerbations and/or improvement in symptoms"; Added asthma initiation requirement that patients with eosinophilic asthma must have prior acute exacerbation(s); Added asthma initiation option that patients with corticosteroid dependent asthma may be currently requiring oral corticosteroids.
April 2022	Addition of requirement for atopic dermatitis: "not used in combination with another non-topical PA medication for atopic dermatitis" and added Appendix 3. Added "emergency" to the requirement "not used for the emergency relief of acute bronchospasm or status asthmaticus"
June 2022	Annual review. Addition of indication per PI update: eosinophilic esophagitis. Per PI update, reduced atopic dermatitis age requirement to 6 months and older
September 2022	Annual review
October 2022	Per PI update, addition of indication prurigo nodularis (PN)
November 2022	Per FEP: addition of initiation requirement for CRSwNP, must be prescribed by or recommended by an ENT
December 2022	Annual review
January 2023	Changed Appendix 2 and moved fluradrenolide tape to very high potency
March 2023	Annual review and reference update
February 2024	Per PI update, decreased age requirement for EoE to 1 year and older and weight at least 15 kg. Added 200 mg to quantity chart for EoE
March 2024	Annual review
April 2024	Per FEP, revised CRSwNP initiation requirement to a 3-month trial of two nasal steroids and one oral steroid. Also added t/f of a PPI to EoE diagnosis initiation criteria
June 2024	Annual review and reference update
September 2024	Annual review

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupixent	<b>Page:</b>	16 of 19

---

October 2024	Per PI update, changed indication to chronic rhinosinusitis with nasal polyps and decreased age to 12 and older. Also added COPD indication. Adjusted dual therapy for Asthma indication to prohibit use with another monoclonal antibody for asthma/COPD. Added Appendix 4 noting monoclonal antibodies for the treatment of Asthma or COPD. Per FEP, added requirement to t/f phototherapy or conventional treatment for prurigo nodularis. Added renewal requirement for patient to be adherent to Dupixent therapy to each indication in renewal criteria.
December 2024	Annual editorial review. Added Appendix 5 and no dual therapy requirement for CRSwNP
March 2025	Annual review

## Keywords

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 7, 2025 and is effective on April 1, 2025.**

**Section:** Prescription Drugs**Effective Date:** April 1, 2025**Subsection:** Topical Products**Original Policy Date:** April 7, 2017**Subject:** Dupixent**Page:** 17 of 19**Appendix 1**

<b>Relative Potency of Topical Calcineurin Inhibitors</b>		
<b>Drug</b>	<b>Dosage Form</b>	<b>Strength</b>
<b>Medium Potency</b>		
Tacrolimus	Ointment	0.1%
<b>Low Potency</b>		
Tacrolimus	Ointment	0.03%
Pimecrolimus	Cream	1%

**Appendix 2**

<b>Relative Potency of Selected Topical Corticosteroids</b>		
<b>Drug</b>	<b>Dosage Form</b>	<b>Strength</b>
<b>Very high Potency</b>		
Augmented betamethasone dipropionate	Ointment, Gel	0.05%
Clobetasol propionate	Cream, Ointment	0.05%
Diflorasone diacetate	Ointment	0.05%
Flurandrenolide	Tape	4 mcg/cm <sup>2</sup>
Halobetasol propionate	Cream, Ointment	0.05%
<b>High Potency</b>		
Amcinonide	Cream, Lotion, Ointment	0.1%
Augmented betamethasone dipropionate	Cream, Lotion	0.05%
Betamethasone dipropionate	Cream, Ointment	0.05%
Betamethasone valerate	Ointment	0.1%
Desoximetasone	Cream, Ointment	0.25%
	Gel	0.05%
Diflorasone diacetate	Cream, Ointment	0.05%
	(emollient base)	
Fluocinonide	Cream, Ointment, Gel	0.05%
Halcinonide	Cream, Ointment	0.1%
Triamcinolone acetonide	Cream, Ointment	0.5%
<b>Medium Potency</b>		
Betamethasone dipropionate	Lotion	0.05%
Betamethasone valerate	Cream	0.1%
Clocortolone pivalate	Cream	0.1%
Desoximetasone	Cream	0.05%

**Section:** Prescription Drugs

**Effective Date:** April 1, 2025

**Subsection:** Topical Products

**Original Policy Date:** April 7, 2017

**Subject:** Dupixent

**Page:** 18 of 19

Fluocinolone acetonide	Cream, Ointment	0.025%
Flurandrenolide	Cream, Ointment, Lotion	0.05%
Fluticasone propionate	Cream	0.05%
	Ointment	0.005%
Hydrocortisone butyrate	Ointment, Solution	0.1%
Hydrocortisone valerate	Cream, Ointment	0.2%
Mometasone furoate	Cream, Ointment, Lotion	0.1%
Prednicarbate	Cream, Ointment	0.1%
Triamcinolone acetonide	Cream, Ointment, Lotion	0.025%
	Cream, Ointment, Lotion	0.1%
<b><i>Low Potency</i></b>		
Alclometasone dipropionate	Cream, Ointment	0.05%
Desonide	Cream	0.05%
Fluocinolone acetonide	Cream, Solution	0.01%
Hydrocortisone	Lotion	0.25%
	Cream, Ointment, Lotion, Aerosol	0.5%
	Cream, Ointment, Lotion, Solution	1%
	Cream, Ointment, Lotion	2.5%
Hydrocortisone acetate	Cream, Ointment	0.5%
	Cream, Ointment	1%

### Appendix 3 - List of Non-Topical PA Medications for Atopic Dermatitis

Generic Name	Brand Name
abrocitinib	Cibinqo
dupilumab	Dupixent
tralokinumab-ldrm	Adbry
upadactinib	Rinvoq

### Appendix 4 - List of Monoclonal Antibodies for Asthma or COPD

Generic Name	Brand Name
benralizumab	Fasenra
dupilumab	Dupixent
mepolizumab	Nucala

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2025
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	April 7, 2017
<b>Subject:</b>	Dupixent	<b>Page:</b>	19 of 19

---

omalizumab	Xolair
reslizumab	Cinqair
tezepelumab-ekko	Tezspire

**Appendix 5 - List of Monoclonal Antibodies for CRSwNP**

<b>Generic Name</b>	<b>Brand Name</b>
dupilumab	Dupixent
mepolizumab	Nucala
omalizumab	Xolair